Scholar Rock Holding Corporation Common Stock
$46.65
-$2.37 (-4.83%)
$45.88Day Range$48.52
Key Statistics
Market Cap
$5.68B
Shares Outstanding
121.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 24, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$48.02
Day High
$48.52
Day Low
$45.88
Volume
3.25M
VWAP
$46.71
Prev Close
$49.02
Transactions
--
Acc. Volume
--
About Scholar Rock Holding Corporation Common Stock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836289 employees301 BINNEY STREET, CAMBRIDGE, MA, 02142857-259-3860IPO May 24, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001727196
- Composite FIGI
- BBG00KT2RRM6
- Share Class FIGI
- BBG00KT2RSD4
- Ticker Root
- SRRK
- SIC Code
- 2836
About Scholar Rock Holding Corporation Common Stock (SRRK) Stock
Scholar Rock Holding Corporation Common Stock (SRRK) closed the 2026-09-18 session at $46.65, down 4.83% versus the previous close (-2.37). The stock opened at $48.02 and traded between $45.88 and $48.52 during that session. Session trading volume was 3.3M shares. The volume-weighted average price (VWAP) is $46.71.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding Corporation Common Stock has a market capitalization of $5.68 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. SRRK is listed on the XNAS exchange. The company employs approximately 289 people. Scholar Rock Holding Corporation Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2018-05-24.
On this page you can find market SRRK stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.